EMA Initiatives and Perspectives on Pharmacogenomics.

Abstract

Pharmacogenomics, the study of variations of DNA and RNA characteristics as related to drug response, has become an integral part of drug development and pharmacovigilance, as reflected by the incorporation of pharmacogenomic data in EU product information. In this short communication we describe recent EMA initiatives intended to further support the implementation of pharmacogenomics in drug- development and surveillance so that patients and public can benefit from the advancements of genomic science and technology.